ClaimsPeople

Nate Silver

Nate Silver is an election forecaster and writer who founded FiveThirtyEight and now publishes the Silver Bulletin newsletter.

617 claims collected, 163 researched, 84 resolved. Report of 10 November 2026, method 0.1.0+28da144b.

Scores by kind of claim

Each kind of claim is scored on its own, out of 100: the share that held up, with the range it likely falls in. Fewer resolved claims give a wider range.

  • Factual claims

    Statements about the present or the past, checked against the record: did they hold up?

    82 76 88

    High confidence, 63 factual claims resolved. From 19 documents, 2012 to 2026; 19 documents sampled from 35 candidates found.

    Not scored: 42 unresolvable, 7 checkable only against their own records.

  • Predictions

    Statements about events outside the person's control, checked once they fell due: did they come true?

    61 47 75

    Medium confidence, 16 predictions resolved. From 8 documents, 2015 to 2025; 19 documents sampled from 35 candidates found.

    Not scored: 12 unresolvable. 10 more fall due later.

    Does not yet allow for how likely each prediction was when made.

  • Promises

    Commitments to the person's or organisation's own future action, with something to deliver: was it delivered?

    67 46 85

    Low confidence, 5 promises resolved. From 4 documents, 2022 to 2025; 19 documents sampled from 35 candidates found.

    Not scored: 7 unresolvable.

All types combined: 77 (likely 72 to 82, high confidence), from 84 claims: 63 factual claims, 16 predictions, 5 promises. It mixes kinds of claim in different proportions for different people, so compare people kind by kind.

Nate Silver's claims

16 claims, sorted by newest said. Choose a claim to read it in full.
VerdictKindSaidClaimTopic
Mixed Prediction 8 Apr 2025 Children's toys will become much more expensive in the US because they are made in heavily tariffed countries such as Vietnam. Prediction · 8 Apr 2025 Economics and markets
Mostly true Prediction 13 Aug 2024 Kamala Harris's bid is inherently difficult and a little bit of a long shot, but her chances of winning the 2024 presidential election are probably better than Joe Biden's were. Prediction · 13 Aug 2024 AI timelines and forecasting
Mostly false Prediction 8 Sep 2023 Biden winning the 2024 presidential election is more likely than Trump winning, which is more likely than someone else winning. Prediction · 8 Sep 2023 Other
Mixed Prediction 8 Sep 2023 Most US voters will not start paying attention to the 2024 presidential election until nine months to a year after September 2023. Prediction · 8 Sep 2023 AI timelines and forecasting
Mostly false Prediction 8 Sep 2023 If Trump does well in Iowa and New Hampshire and Biden has no snafu, Trump and Biden could become their parties' presumptive 2024 nominees as soon as February 2024. Prediction · 8 Sep 2023 Other
Resolved true Prediction 30 Jun 2022 Republicans are heavy favorites to win the House in the 2022 midterms, and the Senate is a toss-up. Prediction · 30 Jun 2022 AI timelines and forecasting
Resolved true Prediction 30 Jun 2022 If Republicans take control of the House in 2023, they are pretty likely to hold COVID panels or investigations. Prediction · 30 Jun 2022 AI policy and governance
Resolved true Prediction 9 Jun 2022 Democrats could hold the Senate in the 2022 midterms if GOP candidates are subpar in a couple of key states or Democrats win the closest races. Prediction · 9 Jun 2022 AI timelines and forecasting
Resolved true Prediction 9 Jun 2022 Democrats holding the House in the 2022 midterms would require an unlikely change in the national environment. Prediction · 9 Jun 2022 AI timelines and forecasting
Mostly true Prediction 29 Jun 2021 It seems very likely that people who received one dose of the J&J COVID vaccine would benefit from a Pfizer or Moderna booster. Prediction · 29 Jun 2021 Biosecurity
Resolved true Prediction 11 Jun 2021 The US could see a rise in COVID cases because of the Delta variant, as in the UK. Prediction · 11 Jun 2021 Biosecurity
Mostly true Prediction 28 Mar 2020 The coronavirus peak in the NYC metro area will probably come sooner than elsewhere in the US. Prediction · 28 Mar 2020 Biosecurity
Mostly true Prediction 25 Sep 2019 Nate Silver guessed that the public would see the contents of the Ukraine call transcript as very inappropriate conduct and would find the White House's quid pro quo spin unresponsive to their concerns. Prediction · 25 Sep 2019 AI timelines and forecasting
Mostly true Prediction 23 Sep 2019 Nate Silver said he still tended not to think public opinion on impeaching Trump would move much, but that it was hard to know. Prediction · 23 Sep 2019 AI timelines and forecasting
Resolved false Prediction 2015 Donald Trump will not win the 2016 Republican presidential nomination. Prediction · 2015 Other
Resolved false Prediction 2015 In all likelihood, Trump could not win the Republican nomination with only a plurality of votes or delegates, because the Republican Party would unite against him. Prediction · 2015 Other
Back to the list

Nate Silver

Open its page

Prediction Biosecurity

“It sure seems very likely that people who got one dose of J&J would benefit from getting a booster of Pfizer or Moderna.”

Nate Silver, writing on X 29 June 2021 Post by @NateSilver538 on X, 2021-06-29 (X)

It seems very likely that people who received one dose of the J&J COVID vaccine would benefit from a Pfizer or Moderna booster.

Mostly true True in substance, wrong in a detail.

The second judge would not resolve this claim; the verdict shown is the first judge's.

What would count as true or false

A hedged ('very likely') prediction, judged against clinical and regulatory evidence available by mid-2022. True: studies (e.g. NIH mix-and-match trials or real-world effectiveness data) show that J&J single-dose recipients who got a Pfizer or Moderna booster had meaningfully higher immune responses or protection than those with no booster, and regulators (FDA/CDC) authorized or recommended mRNA boosters for J&J recipients. Mostly true: a clear benefit is shown, but on narrower measures only (e.g. antibody levels without clinical outcome data). Mixed: evidence of benefit is inconsistent or limited to some subgroups. Mostly false: mRNA boosters gave little benefit over a J&J booster or no booster for most recipients. False: evidence shows no benefit, or net harm, from an mRNA booster for J&J recipients.

Evidence

  1. Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults — VISION Network, 10 States, December 2021–March 2022 CDC, Morbidity and Mortality Weekly Report (MMWR) · 1 April 2022
    “VE against COVID-19–associated emergency department/ urgent care visits was 24% after 1 Jansen dose, 54% after 2 Jansen doses, and 79% after 1 Janssen/1 mRNA dose, compared to 83% after 3 mRNA doses.”
  2. Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming Erasmus University Rotterdam research portal (pure.eur.nl); published in NEJM · 10 March 2022
    “Boosting with any available vaccine was better than not boosting.”
  3. Mix-and-match trial finds additional dose of COVID-19 vaccine safe, immunogenic National Institutes of Health (NIAID media advisory) · 26 January 2022
    “For each primary EUA COVID-19 vaccine, heterologous boosts elicited similar or higher antibody responses as compared to responses to a homologous booster.”

Reasoning

A CDC study from the VISION Network (E1) estimated vaccine effectiveness against emergency department and urgent care visits from December 2021 to March 2022. It was 79% after one Janssen dose plus an mRNA booster, against 24% after a single Janssen dose. An NEJM study (E2) found that boosting J&J-primed people with any available vaccine was better than not boosting. The NIH mix-and-match trial (E4) found that mixed-vaccine boosters produced similar or higher antibody responses than same-vaccine boosters. Together these show a clear benefit, including on clinical outcomes. However, none of the evidence shows that the FDA or CDC authorized or recommended mRNA boosters for J&J recipients, which the criteria require for a fully true verdict.

Cite this claim

Nate Silver, “It seems very likely that people who received one dose of the J&J COVID vaccine would benefit from a Pfizer or Moderna booster.” (said 29 June 2021). Verdict: mostly true. Reliability API, claim c_dc12ab492306, method 0.1.0+28da144b. https://epistacklabs.com/claims/c_dc12ab492306

Claims without a verdict

Is a verdict here wrong, or do you speak for Nate Silver? Reply on the claim's own page, with the form at its foot (how replies work). Verdicts are made automatically; how verdicts and scores are made.